Entezari Morteza, Esmaeili Manuchehr, Yaseri Mehdi
Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti Medical Sciences, Tehran, Iran,
Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1309-13. doi: 10.1007/s00417-014-2691-6. Epub 2014 Jul 2.
To evaluate the efficacy of intravenous erythropoietin (EPO) on improvement of visual function and color vision in patients with recent indirect traumatic optic neuropathy (TON).
In a case series, 18 eyes of 18 patients with diagnosis of indirect TON with duration of less than 2 weeks underwent 20,000 IU intravenous EPO injections daily for 3 days. Best corrected visual acuity (BCVA) and color vision were checked by Ishihara test before, 1, and 3 months after injections. BCVA and color vision were compared before, 1, and 3 months after injections.
The mean BCVA improved from a baseline of 2.21 ± 0.97 to 1.48 ± 1.29 and 1.31 ± 1.27 log MAR at months 1 and 3, respectively. The differences were statistically significant (P = 0.001, P < 0.001). Color vision was changed from a baseline 2.24 ± 4.29 to 2.94 ± 4.64 and 3.41 ± 5.09 plates at months 1 and 3, respectively. We observed some qualitative improvement that was, however, statistically insignificant at the time of evaluation. (P = 0.063, P = 0.068).
This case series showed noticeable effect of EPO on improvement of visual function in patients with recent indirect TON.
评估静脉注射促红细胞生成素(EPO)对近期间接性外伤性视神经病变(TON)患者视觉功能和色觉改善的疗效。
在一个病例系列中,18例诊断为间接性TON且病程小于2周的患者的18只眼睛,每天接受20,000国际单位静脉注射EPO,共注射3天。在注射前、注射后1个月和3个月,通过最佳矫正视力(BCVA)和石原氏试验检查色觉。比较注射前、注射后1个月和3个月的BCVA和色觉。
平均BCVA分别从基线的2.21±0.97改善到注射后1个月和3个月时的1.48±1.29和1.31±1.27 log MAR。差异具有统计学意义(P = 0.001,P < 0.001)。色觉分别从基线的2.24±4.29改善到注射后1个月和3个月时的2.94±4.64和3.41±5.09个色盘。我们观察到一些定性改善,然而,在评估时无统计学意义(P = 0.063,P = 0.068)。
该病例系列显示EPO对近期间接性TON患者的视觉功能改善有显著效果。